| BTX (BTX) | |||
|---|---|---|---|
| 0.2051 0 (0.05%) | 10-17 00:00 | ||
| Open: | 0.1988 | Pre. Close: | 0.205 |
| High: | 0.21 | Low: | 0.181 |
| Volume: | 2,557,644 | Market Cap: | 1(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 0.25 -10000000000 One year: 0.29 -10000000000 |
| Support: | Support1: 0.19 -10000000000 Support2: 0.18 -10000000000 |
| Resistance: | Resistance1: 0.21 -10000000000 Resistance2: 0.25 -10000000000 |
| Pivot: | -10000000000 |
| Moving Averages: | MA(5): MA(20): MA(100): MA(250): |
| MACD: | MACD(12,26): -10000000000.00 -10000000000 Signal(12,26,9): -10000000000.00 -10000000000 |
| %K %D: | %K(14,3): -10000000000.00 -10000000000 %D(3): -10000000000.00 -10000000000 |
| RSI: | RSI(14): -10000000000.00 -10000000000 |
| 52-Week: | High: 200 Low: 0.181 Change(%): |
| Average Vol(K): | 3-Month: -10000000000 10-Days: -10000000000 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BTX ] has closed Bollinger Bands are 0% narrower than normal. |
| Company profile |
|---|
| Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | |
| % Held by Insiders | |
| % Held by Institutions | |
| Shares Short (K) | |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow | |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
